WASHINGTON, May 18 -- The US Food and Drug Administration (FDA) has approved Novavax's Covid-19 vaccine, Nuvaxovid, but only for limited use in specific age and health groups. The decision was announced on Friday and marks a key moment for the company.

According to the FDA, the vaccine is now approved for people aged 65 and older, and for individuals aged 12 to 64 who have at least one health condition that increases their risk of severe illness from Covid-19. However, the did not define what qualifies as an "underlying condition."

In addition, the FDA delayed pediatric studies for children under 12 years old, as clinical trials for that age group have not yet been completed. This means younger children remain ineligible for the Novavax...